Jacobs Levy Equity Management Inc. Has $7.71 Million Holdings in DaVita Inc. (NYSE:DVA)

Jacobs Levy Equity Management Inc. decreased its position in shares of DaVita Inc. (NYSE:DVA) by 93.0% during the 1st quarter, Holdings Channel reports. The institutional investor owned 55,852 shares of the company’s stock after selling 746,827 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in DaVita were worth $7,710,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in DaVita by 2.4% during the 4th quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock worth $662,161,000 after buying an additional 145,711 shares in the last quarter. Gates Capital Management Inc. lifted its holdings in DaVita by 3.1% during the 4th quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock worth $94,895,000 after buying an additional 27,660 shares in the last quarter. 8 Knots Management LLC acquired a new position in DaVita during the 4th quarter worth $89,504,000. Allianz Asset Management GmbH lifted its holdings in DaVita by 63.9% during the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after buying an additional 213,992 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC acquired a new position in DaVita during the 4th quarter worth $53,076,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Down 1.9 %

DVA stock traded down $2.69 during trading hours on Tuesday, reaching $136.47. 630,502 shares of the stock were exchanged, compared to its average volume of 837,436. The firm’s 50-day moving average is $140.60 and its 200-day moving average is $131.73. The company has a market cap of $11.97 billion, a price-to-earnings ratio of 15.51, a PEG ratio of 1.05 and a beta of 0.87. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $147.93.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same period in the prior year, the business posted $1.58 EPS. The company’s quarterly revenue was up 6.9% on a year-over-year basis. On average, equities research analysts expect that DaVita Inc. will post 9.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on DVA shares. Truist Financial upped their price objective on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. Barclays increased their price target on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research note on Monday, May 6th. TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $146.00.

Insider Transactions at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.